Download our app Order a test

Helping you to make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Introducing
Cancer A-Z

Our brand new patient-focused app

Find out more

Download now

Common requests

Find answers to some of your most frequently asked questions

Medical Professionals

Do I need to sign any paperwork?In which countries are RGCC tests approved for use?How many types of cancer are tested when RGCC says “all types of cancer”?Can RGCC test for BRAF drugs?

Patient Information

How long do test results take to process?Are your testing methods accredited internationally?

Cancer tests

New methods and reliable tests to help deliver personalised treatment

RGCC CAMBISeq®

RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with a crucial insight into cancer.  The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their […]

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]

View test

Immune-Frame

Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyse the status of a patient’s immune system, and to provide ongoing information about […]

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]

View test

ChemoSNiP

ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug. ChemoSNiP analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments […]

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs). Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of […]

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests […]

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments […]

View test

Oncotrail RGCC

Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]

View test

Oncotrace RGCC

Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]

View test

Oncocount RGCC

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

How cancer cells evade the immune system

Posted: 20th October 2021
Categories: Industry news

Mutations in cancer-suppressing genes that block cell growth may explain why some cancers evade the body’s immune system, scientists have established. A US team has identified 100 “mutated tumor suppressor genes” that affect the body’s ability to spot and destroy cancer cells in mice. While at an early stage, identifying genetic mutations could lead to […]

Read more

Molecular boost for cancer immunotherapies

Posted: 11th October 2021
Categories: Industry news

Scientists have identified a new synthetic molecular code that could improve a patient’s response to an effective cancer treatment, known as PD-1 blockade immunotherapy. The team from Kyoto University have created a new molecular code that ensures a supply of energy to cancer-killing T-cells. The molecular code is highly effective at targeting cancer cells when […]

Read more

Celebrating our inaugural virtual RGCC Gathering

24th September 2021 - 26th September 2021
Zug, Switzerland

RGCC Network doctors from across the world set their alarm clocks and tuned in for RGCC’s first ever virtual RGCC Gathering on 24th-26 September. Broadcasting live from the beautiful lakeside city of Zug, the event treated virtual guests to more than 23 hours of lectures and presentations delivered by RGCC’s very own scientists. Doctors from […]

Read more

Researchers identify a key enzyme in tumours

Posted: 29th September 2021
Categories: Industry news

Researchers have identified a key enzyme that cancerous tumours rely on to grow and spread within the body. Described as cancer’s “Achilles Heel”, scientists believe that targeting this enzyme stops tumour cells from growing and spreading. The findings could accelerate the development of new treatments for solid-tumour cancers. Solid cancerous tumours rely on an available […]

Read more

ctDNA accurate at diagnosing rectal cancer relapse

Posted: 17th September 2021
Categories: Industry news

Combining circulating tumour DNA (ctDNA) with magnetic resonance imaging (MRI) can more accurately predict the likelihood of locally advanced rectal cancer (LARC) returning after treatment, Chinese scientists have found. In a new study published in PLOS Medicine, researchers describe how combining the techniques improved diagnosis and could improve treatment and outcomes for patients. In addition, […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more